TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
Sponsored by TG Therapeutics, Inc.
About this trial
Last updated 6 years ago
Study ID
TGR-GA-106
Status
Completed
Type
Interventional
Phase
Phase 1
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 8 years ago
What is this trial about?
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in
combination with obinutuzumab (Gazyva) and chlorambucil in patients with chronic lymphocytic
leukemia.
What are the participation requirements?
Inclusion Criteria
- Confirmed Chronic Lymphocytic Leukemia (CLL)
- Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
- Ability to swallow oral medication
Exclusion Criteria
- Known hepatitis B virus, hepatitis C virus or HIV infection
- Primary central nervous system lymphoma or known intracranial involvement
- Autologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months